| 000 | 01390 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250517181306.0 | ||
| 264 | 0 | _c20180214 | |
| 008 | 201802s 0 0 fre d | ||
| 022 | _a1769-6917 | ||
| 024 | 7 |
_a10.1016/j.bulcan.2017.09.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aClatot, Florian | |
| 245 | 0 | 0 |
_a[Clinical relevance of ESR1 circulating mutations detection in hormone receptor positive metastatic breast cancer]. _h[electronic resource] |
| 260 |
_bBulletin du cancer _cJan 2018 |
||
| 300 |
_a46-54 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAromatase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast _xpathology |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aDNA Mutational Analysis _xmethods |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aEstrogen Receptor alpha _xgenetics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiquid Biopsy _xmethods |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aSelective Estrogen Receptor Modulators _xtherapeutic use |
| 700 | 1 | _aPerdrix, Anne | |
| 700 | 1 | _aSefrioui, David | |
| 700 | 1 | _aSarafan-Vasseur, Nasrin | |
| 700 | 1 | _aDi Fiore, Frédéric | |
| 773 | 0 |
_tBulletin du cancer _gvol. 105 _gno. 1 _gp. 46-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bulcan.2017.09.002 _zAvailable from publisher's website |
| 999 |
_c27685550 _d27685550 |
||